Regeneron Pharmaceuticals, Inc. (REGN) EPS CAGR:5.31%(TTM)
EPS CAGR uses precomputed diluted earnings history where available.
Over longer horizons, Regeneron Pharmaceuticals, Inc.'s EPS CAGR averages 2.06% over 3 years and 5.70% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. EPS (Earnings Per Share) CAGR measures how Regeneron Pharmaceuticals, Inc.'s earnings per share have grown. This is a key metric for valuation and reflects profitability on a per-share basis.
REGN EPS CAGR Chart
Regeneron Pharmaceuticals, Inc. (REGN)
REGN Quarterly EPS Growth (YoY)
EPS growth vs the same quarter one year earlier, last 20 quarters.
REGN EPS CAGR History
| Year | Start EPS | End EPS | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $40.90 | $43.07 | +$2.17 | +5.31% | +5.31% |
| 2024 | $37.05 | $40.90 | +$3.85 | +10.39% | +10.39% |
| 2023 | $40.51 | $37.05 | $-3.46 | -8.54% | -8.54% |
| 2022 | $76.40 | $40.51 | $-35.89 | -46.98% | -46.98% |
| 2021 | $32.65 | $76.40 | +$43.75 | +134.00% | +134.00% |
| 2020 | $19.38 | $32.65 | +$13.27 | +68.47% | +68.47% |
| 2019 | $21.29 | $19.38 | $-1.91 | -8.97% | -8.97% |
| 2018 | $11.27 | $21.29 | +$10.02 | +88.91% | +88.91% |
| 2017 | $8.55 | $11.27 | +$2.72 | +31.81% | +31.81% |
| 2016 | $6.17 | $8.55 | +$2.38 | +38.57% | +38.57% |
| 2015 | $3.36 | $6.17 | +$2.81 | +83.63% | +83.63% |
| 2014 | $4.23 | $3.36 | $-0.87 | -20.57% | -20.57% |
| 2013 | $7.92 | $4.23 | $-3.69 | -46.59% | -46.59% |
| 2012 | $-2.45 | $7.92 | +$10.37 | +0.00% | N/A |
| 2011 | $-1.26 | $-2.45 | $-1.19 | +0.00% | N/A |
| 2010 | $-0.85 | $-1.26 | $-0.41 | +0.00% | N/A |
| 2009 | $-1.05 | $-0.85 | +$0.20 | +0.00% | N/A |
| 2008 | $-1.59 | $-1.05 | +$0.54 | +0.00% | N/A |
| 2007 | $-1.77 | $-1.59 | +$0.18 | +0.00% | N/A |
| 2006 | $-1.71 | $-1.77 | $-0.06 | +0.00% | N/A |
| 2005 | $0.75 | $-1.71 | $-2.46 | -328.00% | N/A |
| 2004 | $-2.13 | $0.75 | +$2.88 | +0.00% | N/A |
| 2003 | $-2.83 | $-2.13 | +$0.70 | +0.00% | N/A |
| 2002 | $-1.81 | $-2.83 | $-1.02 | +0.00% | N/A |
| 2001 | $-0.66 | $-1.81 | $-1.15 | +0.00% | N/A |
| 2000 | $-0.74 | $-0.66 | +$0.08 | +0.00% | N/A |
| 1999 | $-0.28 | $-0.74 | $-0.46 | +0.00% | N/A |
| 1998 | $-0.40 | $-0.28 | +$0.12 | +0.00% | N/A |
| 1997 | $-1.32 | $-0.40 | +$0.92 | +0.00% | N/A |
Quarterly EPS: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $6.99 | -14.9% | -7.8% |
| Q4 2025 | $8.21 | -41.7% | -3.8% |
| Q3 2025 | $14.09 | +6.4% | +13.6% |
| Q2 2025 | $13.24 | +74.7% | -0.1% |
| Q1 2025 | $7.58 | -11.1% | +13.1% |
| Q4 2024 | $8.53 | -31.2% | -21.6% |
| Q3 2024 | $12.40 | -6.4% | +30.8% |
| Q2 2024 | $13.25 | +97.8% | +46.4% |
| Q1 2024 | $6.70 | -38.4% | -12.3% |
| Q4 2023 | $10.88 | +14.8% | -2.8% |
| Q3 2023 | $9.48 | +4.8% | -18.7% |
| Q2 2023 | $9.05 | +18.5% | +21.2% |
| Q1 2023 | $7.64 | -31.7% | -11.3% |
| Q4 2022 | $11.19 | -4.0% | -46.7% |
| Q3 2022 | $11.66 | +56.1% | -24.1% |
| Q2 2022 | $7.47 | -13.2% | -74.7% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Leonard S. Schleifer